North East and North Cumbria
ICS Formulary
ICS Formulary
1 Gastro-intestinal system
01-09-01 Other prepatations for biliary disorders
| Obeticholic acid |
|
Formulary
|
|
 MHRA Drug Safety Update (April 2018): Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
|
| Odevixibat Bylvay® |
|
Formulary
|
|
|
NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis |
|
|
Links
- County Durham and Tees Valley Guidance for Prescribing and Monitoring in Post Bariatric Surgery in Primary Care
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities- MHRA Drug Safety Update (April 2018): Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring
- NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis
- NICE TA443 Obeticholic acid for treating primary biliary cholangitis
- North of Tyne, Gateshead and North Cumbria - Management of patients, post-bariatric surgery in primary care
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence